Skip to main content
. 2020 May 18;3:100026. doi: 10.1016/j.vpoa.2020.100026

Table 2.

Serological (ELISA, IFAT, SNAP tests) and PCR (conjunctival swabs and bone marrow aspirates) follow-up of dogs.

Days Group 1 Untreated control
Group 2 Frontline Tri-Act treated
Positive n / N (%), Dog ID, Technique
Serology PCR Serology and PCR
Day 112 1/20 (5 %) 0/20 (0 %) 0 / 20 (0 %)
6 PCR conjunctival swabs ELISA, PCR conjunctival swabs
ELISA
Day 140 2/20 (10 %) 2/20 (10 %) 0 / 20 (0 %)
6, 23 6, 37 SNAP, PCR conjunctival swabs
SNAP PCR conjunctival swabs
Day 168 3/20 (15 %) 4/20 (10 %) 0 / 20 (0 %)
6, 23, 33 6, 23, 33, 37 SNAP, PCR conjunctival swabs
SNAP PCR conjunctival swabs
Day 252 4/20 (10 %) 4/20 (10 %) 0 / 20 (0 %)
6, 23, 33, 37 6, 23, 33, 37 ELISA, SNAP, IFAT, PCR conjunctival swabs & bone marrows
ELISA, SNAP, IFAT PCR conjunctival swabs & bone marrows
Day 350 6 / 20 (20 %) 7 / 20 (20 %) 0 / 20 (0 %)
3, 6, 23, 30, 33, 37 3, 6, 15, 23, 30, 33, 37 ELISA, SNAP, IFAT, PCR conjunctival swabs & bone marrows
ELISA, SNAP, IFAT PCR conjunctival swabs & bone marrows
p = 0.02 (Fischer’s exact test compared to treated group) p = 0.0083(Fischer’s exact test compared to treated group)

Group 1: Dogs were treated with sterile water, intended as a "sham-treatment" to maintain blinding, as a topical spot-on on Days 0, 28, 56, 84, 112, 140 and 168 Group 2: Dogs were treated with Frontline Tri-Act® as a topical spot-on on Days 0, 28, 56, 84, 112, 140 and 168.